Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Encorafenib
Related studies linked through entity extraction aliases.
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Melanoma Metastasized to the Brain and Steroids
- Status
- RECRUITING
- Phase
- PHASE2
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)
- Status
- COMPLETED
- Phase
- PHASE2
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
- Status
- UNKNOWN
- Phase
- PHASE1